Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 12/20 | 1.00 |
| ▸ | PTPN2 | P17706 | 4/20 | 1.00 |
| ▸ | F3 | P13726 | 4/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | USP7 | Q93009 | 3/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 3/20 | 1.00 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 1.00 |
| ▸ | PSMB11 | A5LHX3 | 2/20 | 1.00 |
| ▸ | PSMA7 | O14818 | 2/20 | 1.00 |
| ▸ | PLA2G1B | P04054 | 2/20 | 1.00 |
| ▸ | PTPRC | P08575 | 2/20 | 1.00 |
| ▸ | PTPRF | P10586 | 2/20 | 1.00 |
| ▸ | PSMB1 | P20618 | 2/20 | 1.00 |
| ▸ | CES1 | P23141 | 2/20 | 1.00 |
| ▸ | ACP1 | P24666 | 2/20 | 1.00 |
| ▸ | PSMA1 | P25786 | 2/20 | 1.00 |
| ▸ | PSMA2 | P25787 | 2/20 | 1.00 |
| ▸ | PSMA3 | P25788 | 2/20 | 1.00 |
| ▸ | PSMA4 | P25789 | 2/20 | 1.00 |
| ▸ | PSMB8 | P28062 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oleanolic_Acid SCHEMBL71070 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2F3POLBUSP7 | |
| Oleanolic_Acid SCHEMBL15382987 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2F3POLBUSP7 | |
| Oleanolic_Acid SCHEMBL13455967 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2F3POLBUSP7 | |
| Oleanolic_Acid SCHEMBL12313106 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2F3POLBUSP7 | |
| Oleanolic_Acid SCHEMBL18688362 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2F3POLBUSP7 | |
| Oleanolic_Acid SCHEMBL24916648 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2F3POLBUSP7 | |
| Oleanolic_Acid SCHEMBL21892159 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2F3POLBUSP7 | |
| Oleanolic_Acid SCHEMBL22009261 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2F3POLBUSP7 | |
| Oleanolic_Acid SCHEMBL20904290 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2F3POLBUSP7 | |
| Oleanolic_Acid SCHEMBL16999276 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2F3POLBUSP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020068689-A1 | TERPINOID DERIVATIVES AND USES THEREOF | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2020-04-02 | — | — | WO | disclosed |
| US-20170260227-A1 | C17-ALKANEDIYL AND ALKENEDIYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF | REATA PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-9593074-B2 | C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof | REATA PHARMACEUTICALS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20140287030-A1 | ANTILEISHMANIAL COMPOSITIONS AND METHODS OF USE | OHIO STATE INNOVATION FOUNDATION (US) | 2014-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140287030-A1 | ANTILEISHMANIAL COMPOSITIONS AND METHODS OF USE | ENPP2, EPX, MPI | PTPN1 2525/4885PTPN2 1825/4885F3 3167/4885 |
| US-20170260227-A1 | C17-ALKANEDIYL AND ALKENEDIYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF | ALOX12, ALOX15, ALOX15B | PTPN1 4691/4885PTPN2 4752/4885F3 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.